Navigation Links
ECLIPSE Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials
Date:9/19/2007

out ECLIPSE

ECLIPSE is an international, multicenter, randomized, placebo-controlled single-dose trial conducted at 48 trials sites in United States, Romania and Bulgaria between 2005 and 2006. ECLIPSE investigators enrolled patients with heart failure (New York Heart Association Class III or IV) for at least three months duration due to left ventricular systolic dysfunction and who had a left ventricular ejection fraction (LVEF) of 40 percent or less.

Investigators assessed patients' inclusion criteria for up to two weeks prior to randomization. Suitable candidates underwent insertion of a balloon- floatation pulmonary artery catheter to assess final eligibility criteria. Final doses of cardiac concomitant medications were administered at least two hours prior to catheter insertion. Following catheter insertion, patients entered into a two- to 20-hour stabilization period. Researchers completed hemodynamic assessments periodically during this period to determine final subject eligibility. Potential participants then entered a two-hour baseline period. If a participant met all criteria during the baseline period, he or she was randomly assigned to one of four groups and received a single once- daily oral tablet of placebo or of 15, 30 or 60 milligrams (mg) tolvaptan. Investigators followed participants for up to 24 hours for assessments.

"The ECLIPSE data add` to our existing knowledge about tolvaptan and its prospective uses," said Taro Iwamoto, CEO, COO and President of Otsuka Pharmaceutical Development & Commercialization, Inc. "Tolvaptan, as one of our most advanced candidate therapies, represents the successful application of Otsuka's expertise in the research and development of new medicines."

About Heart Failure

More than 14 million people in Europe(1) and five million U.S. residents(2) have heart failure (HF), a serious chronic condition in which the heart cannot effectively pump blood. The direct and indirect U.S. health care e
'/>"/>

SOURCE Otsuka America Pharmaceutical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
2. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
3. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
4. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. New Data Suggests Less Abuse-Related Effects For OROS Methylphenidate
7. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
8. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
9. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... EHE International, the recognized leader in preventive medicine and annual ... David Abrams M.D . in Tarzana, CA ... Through David Abrams M.D ., EHE members in the ... to EHE,s preventive care programs to help proactively maintain their ... Abrams M.D. to its growing private provider network. With Dr. ...
(Date:9/16/2014)... 16, 2014  Decision Resources Group finds that the rheumatoid arthritis ... 2013 to over $18.2 billion in 2023 in the ... Germany , Italy , Spain ... Japan . TNF-alpha inhibitors will remain the leading drug ... but growth will be constrained and patient shares will decline due ...
(Date:9/16/2014)... DUBLIN , Sept. 16, 2014 ... addition of the "Global Laparoscopy Devices Industry ... The Global Laparoscopy Devices Industry Report ... the current state of the global laparoscopic devices. ... of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Global Laparoscopy Devices Industry Report 2014 2
(Date:9/16/2014)... the University of California, San Diego School of Medicine ... assess the safety and efficacy of a new monoclonal ... most common form of blood cancer in adults. ... used by embryonic cells during early development and exploited ... the latter responsible for 90 percent of all cancer-related ...
(Date:9/16/2014)... LINCOLN, R.I. (PRWEB) September 16, 2014 ... from Sunday, Sept. 14, through Saturday, Sept. 20, ... make sure children are safe and secure while in ... from the National Traffic Highway Safety Administration (NHTSA), ... did not read the instruction manual when installing child ...
(Date:9/16/2014)... 16, 2014 CarePoint Health is ... Leigh Montes, MD, has joined our expanded Bariatric ... Hospital. Our system welcomes Dr. Montes to the ... surgical weight loss center, helps patients achieve long-term ... surgery procedures, including Gastric Sleeve, Gastric Bypass, LAP-BAND ...
(Date:9/16/2014)... Pittsburgh, PA (PRWEB) September 16, 2014 ... recovering well today after undergoing successful heart transplantation surgery ... , Mr. Tekulve, who spent most of his 16-year ... the team as a commentator for Root Sports Pittsburgh, ... his transplant surgeon, Stephen Bailey, MD, surgical director of ...
(Date:9/16/2014)... (HealthDay News) -- Illegal drug use among teens in the ... federal report. Encouragingly, the new study also found ... products among young people between the ages of 12 and ... survey of 70,000 people aged 12 and older across the ... or abuse problems among this age group also dropped from ...
Breaking Medicine News(10 mins):Health News:Novel drug targeting leukemia cells enters clinical trial 2Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2
... Chemo-radiation therapy looks to kill cells on organ,s surface, ... (HealthDay News) -- Patients are being recruited for a ... protocol for pleural mesothelioma, a cancer of the lung,s ... , Currently, the standard treatment is to remove the ...
... how the nervous system and the immune system interact, scientists at The ... which the brain and the spleen communicate. , ... Manhasset, NY (PRWEB) ... nervous system and the immune system interact, scientists at The Feinstein ...
... T. Kennedy DSc, Dean of Tufts University,s Gerald J. ... Policy announced the 3rd Annual Friedman School Symposium, a ... facing industry, policy-makers, academics and thought leaders in the ... September 24th to 26th, 2008. , Fifteen experts will ...
... for Advanced Medical,Education (IAME) announces the release of ... program. Produced in response to a,strong demand by ... 3 CME,credits required for Mammography Center accreditation., ... course,available online at the CME Center of IAME,s ...
... 15 Percent Increase in Prescription Drug,Costs in ... HealthLeaders-InterStudy, NASHVILLE, Tenn., July 21 ... intelligence, reports that Excellus,BlueCross BlueShield will continue ... and public education efforts. According to the,new ...
... (SPI) has,received an R&D contract award from the ... drug candidate for hearing regeneration. SPI has,developed a ... inner ear of mammals involving p27Kip1, a cyclin ... division or proliferation in,many developing cells and tissues ...
Cached Medicine News:Health News:Lung Cancer Trial Targets Asbestos-Related Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 3Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 3Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product 2
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
... ideal hemostatic gauze for a variety of inpatient ... iX is easy to handle and can be ... sites that are often a challenge faced by ... used to control bleeding in outpatient procedures such ...
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Microscissors : Horizontal Scissors...
Medicine Products: